Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Key Takeaways Mounjaro (tirzepatide) mimics both GLP-1 and GIP receptors, differentiating it from GWegovy and Ozempic, which solely target GLP-1
like better focus, less fatigue, or even improved recovery, without even realizing that L-Carnitine is playing a part
A healthy lifestyle WHO recommendations
Congratulations on the launch
Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
Approximately 90% of GLP-1 is metabolized by DPP-4 before reaching the central venous circulation (Holst and Deacon, 2005), and the peak circulating concentration of active GLP-1 (7-36)NH 2 after a meal in healthy subjects is usually less than 10 pmol/L due to the rapid degradation of DPP-4 (Bak et al., 2014)
US$ 26.28
US$ 20.06
US$ 23.95
US$ 25.36
US$ 27.56
US$ 24.07
US$ 25.23
US$ 20.00
US$ 28.34
US$ 20.45
